content_image/193588.jpg
## Our Diversified Portfolio and Pipeline 

This foundation, in turn, made it possible for us to work through challenges and seize opportunities in 2012, while positioning ourselves for a successful future. 

Most notably, it helped us to manage the losses of exclusivity of Plavix  and Avapro / Avalide . Having long known that two of our biggest products were going off patent in 2012 and that the financial impact would be consider- able, we planned accordingly and executed successfully. We strength- ened our diversified portfolio with new products and new indications. We achieved significant clinical advances. And we renewed our commitment to productivity. 

## Cardiovascular Disease 

In the last weeks of the year, we gained several approvals for Eliquis , a new medication for the prevention of stroke and systemic embolism for adult patients with nonvalvular atrial fibrillation, or NVAF. Specifically, Eliquis  was approved in Europe, Canada, Japan and the United States. This was an important development for patients. Atrial fibrillation is a common heart arrhythmia that affects millions of people worldwide. It is a condition that significantly increases the risk of stroke as well as the bur- den to patients who suffer a stroke. This was also an important devel- opment for physicians.  Eliquis  is the only anticoagulant with proven superior risk reduction versus war- farin in the three critical outcomes of stroke prevention, major bleeding and all-cause death in patients with NVAF. For nearly 60 years, warfarin 

<img src='content_image/193588.jpg'>

“Simply stated, our BioPharma Transformation has been built on a solid foundation of realistic expectations, high aspirations and a commitment to excellence that runs throughout our entire company.” 

has been the standard of care for this patient population. 

Finally, this was a very positive development for our company and for our alliance with Pfizer, because it further underscored the value of our partnership and the leadership role both companies continue to play in providing innovative medicines for the treatment of cardiovascular disease. 

## Diabetes 

In 2012, we continued to expand our Onglyza  franchise and delivered a 50% increase in year-over-year sales. 

We also acquired Amylin, a biophar- maceutical company specializing in diabetes and other metabolic 

diseases, and with it, three mar- keted products, including Byetta and Bydureon , and a state-of-the-art manufacturing plant in Ohio. And very importantly, we also expanded our 5-year-old diabetes partnership with AstraZeneca. 

Toward the end of the year, we gained European Commission approval for Forxiga , a once-daily oral medication that provides a completely new option to improve glycemic control in adult patients with type 2 diabetes. 

In light of all of these developments, we are now able to offer three innova- tive classes of medicines to help address the diverse needs of patients with type 2 diabetes. This is good news for our company and for the patients we serve. Type 2 diabetes is a chronic, progressive disease that is growing in prevalence across the globe. According to the World Health Organization (WHO), there are an estimated 346 million people with diabetes worldwide. By 2030, that number is projected to double. Consequently, there is a real need for new treatment options. 

## Immuno-Oncology 

Yervoy  continued to get established in markets throughout the world. Global sales increased 96% over the previous year, and this breakthrough product demonstrated an unprec- edented 5-year survival curve for melanoma patients. 

Our Research and Development team also made progress with two potential products – nivolumab, which is in Phase III trials for lung, renal and skin cancers, and elotuzumab, for multiple myeloma. 

These developments reaffirmed Bristol-Myers Squibb’s position as 

